Press Releases :: IceCure Medical Ltd. (ICCM)

Skip to main content Skip to section navigation Skip to footer

May 28, 2025 8:30 am EDT

IceCure Medical Reports First Quarter 2025 Financial Results

May 21, 2025 8:30 am EDT

IceCure to Report First Quarter 2025 Financial & Operational Results on May 28, 2025

May 06, 2025 8:30 am EDT

IceCure Receives High Level of Interest from Breast Surgeons at ASBrS 2025 Annual Meeting Following Recent Positive FDA Development on ProSense® Cryoablation

Apr 30, 2025 8:30 am EDT

IceCure Announces Positive FDA Development: Understanding on Path Forward for Marketing Authorization of ProSense® Cryoablation in Women 70+ with Early-Stage Breast Cancer

Apr 28, 2025 8:30 am EDT

IceCure Exhibits ProSense® & Sponsors Breast Cryoablation Courses at the Society of Breast Imaging Symposium

Apr 22, 2025 8:30 am EDT

IceCure's ProSense® Featured at European Conference on Interventional Oncology with an Emphasis on Breast Cancer Cryoablation

Mar 27, 2025 8:30 am EDT

IceCure Medical Reports 2024 Financial Results: 42% Growth in ProSense® Cryoablation Sales in North America

Mar 24, 2025 8:30 am EDT

IceCure's ICESECRET Kidney Cancer Cryoablation Study Interim Results Presented at European Association of Urology Conference in Spain: 88.7% Recurrence-Free Rate

Mar 21, 2025 8:30 am EDT

IceCure Medical to Report 2024 Full Year Financial & Operational Results on March 27, 2025

Mar 20, 2025 8:30 am EDT

IceCure Reports Updated Timeline and Progress with FDA Regarding Marketing Authorization for ProSense® Cryoablation in Early-Stage Breast Cancer

Select a page:

rss_feed News RSS

IceCure Medical HQ: 7 Ha’Eshel St., PO Box 3163, Caesarea, 3079504, Israel

© 2025 All Rights Reserved IceCure Medical

Branding by

Terms of Use | Privacy | Last Updated: April 9, 2023